Phaco system reduces occlusion
August 15th 2010Results of a controlled clinical trial show that a software upgrade for performing torsional ultrasound with a proprietary handpiece and phaco system achieves its purpose of minimizing occlusion during phacoemulsification with consequences for improving the safety and efficiency of cataract removal.
Real-time optical coherence tomography guidance optimizes cataract surgery
August 15th 2010Experience using a proprietary femtosecond laser with an integrated, real-time optical coherence tomography imaging device highlights the advantages provided by this technology in performing cataract surgery and its potential to raise the bar for functional and safety outcomes.
Combination ophthalmic viscosurgical device provides versatility
August 15th 2010A combination ophthalmic viscosurgical device, 1.6% sodium hyaluronate, fills the bill during cataract surgery by combining the benefits of cohesive and dispersive agents in a single vial instead of two separate vials, making it more economical and simplifying surgery.
U.S. News names best eye hospitals
August 4th 2010The Bascom Palmer Eye Institute at the University of Miami and the Wilmer Eye Institute at Johns Hospitals Hospital, Baltimore, have been named to the first and second spots, respectively, in the ophthalmology category of U.S. News and World Report?s 2010?2011 list of best hospitals for the seventh consecutive year.
B+L voluntarily recalls eye vitamins
August 4th 2010Bausch + Lomb (B+L) is voluntarily recalling an eye vitamin (PreserVision Eye Vitamin AREDS 2 Formula with Omega 3) after receiving ?a small number of reports predominantly within a specific age group, age 70 and older, who reported difficulty swallowing or a choking sensation when taking the soft gel,? according to the company.
Alcon recalls microsurgical system
August 4th 2010Alcon Laboratories is recalling a microsurgical system (Constellation Vision System) after identifying software and hardware issues associated with unexpected loss of power, unintended system error messages, unresponsive touch screens, and system setting and infusion performance problems.
Phase III study to investigate dry eye therapy
July 9th 2010EyeGate Pharma has begun enrolling patients in the ALLUVION (EvALuation of Dexamethasone Phosphate DeLivered by OcUlar Iontophoresis for the Treatment of Dry Eye in the Controlled Adverse EnVIrONment Model) pivotal phase III study of EGP-437 for the treatment of dry eye syndrome.